| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―Dec―18 |
SARS-CoV-2 infection and gut-lung axis: the potential role of rifaximin |
Taghreed N. Almanaa, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Maii A. Abdelnaby, Athanasios Alexiou, Marios Papadakis, Islam E. Abo-ElFetoh, Gaber El-Saber Batiha |
| 2 |
[GO] |
2025―Nov―30 |
Lingering echoes of SARS-CoV-2: mechanistic insights and management of long COVID syndrome |
Jagat Pal Yadav, Seema Yadav, Nimesh Kumar Dubey, Indra Pal Yadav, Prateek Pathak, Amita Verma |
| 3 |
[GO] |
2025―Nov―22 |
Persistent inflammatory cytokine signature in long Covid-19 patients: a meta-analysis |
Waleska Dornas, João Pedro Reis, Tales Eduardo Belilo, Leonardo Gomes Vaz, Helena Horta Nasser, Maria de Lourdes de Souza Maia, Alexandre Figueiredo, André Gomes Tcherniacovski, Lourdes Coral Contreras Montenegro, Xiaofeng Yang, Helton C Santiago |
| 4 |
[GO] |
2025―Oct―13 |
From infection to intervention: post-acute sequelae of SARS-CoV-2 infection and cardiovascular risk |
Rufaida Wasim |
| 5 |
[GO] |
2025―Sep―24 |
Unveiling the secret of cellular metamorphosis: the crucial role of EndMT mechanisms in COVID-19-induced pulmonary fibrosis |
Xin Zhang, Xia Tong, Ruijie Hou, Pengbo Wang, Yan Mo, Lanlan Zhang |
| 6 |
[GO] |
2025―Aug―29 |
MicroRNAs in SARS-CoV-2 infection: emerging modulators of inflammation, pathogenesis, and therapeutic potential |
Mohammad Fayyad-Kazan |
| 7 |
[GO] |
2025―Aug―27 |
The potential role of carvedilol in COVID-19 management: perspective and take-away |
Hayder M. Al-Kuraishy, Maii A. Abdelnaby, Marios Papadakis, Athanasios Alexiou, Gaber El-Saber Batiha |
| 8 |
[GO] |
2025―Aug―12 |
COVID-19 in comorbid chronic diseased patients, pregnant and lactating women: pathophysiology, available drug treatment, and the most suitable protocol regimen in each group |
Hend M. Mohamed, Yara Y. Elkholy, Yara M. Mokhtar, Mirna A. Orady, Heba Sh. Elmetwaly, Hend Mo. Abdelwahab, Yasmeen S. Abdelrady, Mohamed M. Elgohary, Mohamed Kh. Elmahdy |
| 9 |
[GO] |
2025―Jul―29 |
Effect of N-Acetylcysteine on mortality in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials |
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Kaeshaelya Thiruchelvam |
| 10 |
[GO] |
2025―Jul―07 |
Long COVID syndrome: exploring therapies for managing and overcoming persistent symptoms |
Dhrita Chatterjee, Kousik Maparu |
| 11 |
[GO] |
2025―Jul―01 |
Aryl-hydrocarbon receptor dysregulation and its correlation with immunomodulatory markers in COVID-19 patients |
Abeda Mazari, Mohammad Hossein Nicknam, Sara Assadiasl, Maryam Sadr, Hanieh Mojtahedi, Maryam Ahmadi, Sina Enayat, Alireza Asgari, Narjes Soleimanifar |
| 12 |
[GO] |
2025―Apr―12 |
Correction: Vitamin D: a key player in COVID-19 immunity and lessons from the pandemic to combat immune-evasive variants |
Hussein Sabit, Shaimaa Abdel-Ghany, Mahmoud S. Abdallah, Osama Abul-Maaty, Ahmed I. Khoder, Nabil A. Shoman, Mohamed Sameh Farrag, Pavel Martasek, Ayman M. Noreddin, Mahmoud Nazih |
| 13 |
[GO] |
2025―Mar―08 |
The association between glucocorticoids and long COVID |
Yan Zhao, Guangting Zeng |
| 14 |
[GO] |
2025―Feb―21 |
Long COVID has variable incidence and clinical presentations: our 6-country collaborative study |
Sandor Szabo, Iryna Muzyka, Veronika Muller, Attila J. Szabo, Attila Szijártó, Klara Gyires, Tamas Doczi, Jozsef Janszky, Andreas Stengel, Siri Göpel, Antonia Trichopoulou, Rafael Diaz, Nicte Camacho, George Malatinszky, Nils Lambrecht, Oksana Zayachkivska |
| 15 |
[GO] |
2024―Dec―23 |
Across-the-board review on Omicron SARS-CoV-2 variant |
Rufaida Wasim, Asad Ahmad |
| 16 |
[GO] |
2024―Nov―27 |
Evaluating diclofenac’s risks in COVID-19: strategies for mitigating adverse outcomes |
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Kaeshaelya Thiruchelvam |
| 17 |
[GO] |
2024―Nov―13 |
Role of intravenous vitamin C on outcomes in hospitalized patients with moderate or severe COVID-19: a real life data of Turkish patients |
Burak Uz, Özgür İnce, Can Gümüş, Feyzi Gökosmanoğlu, Emrah Gökay Özgür, Gülnaz Nural Bekiroğlu |
| 18 |
[GO] |
2024―Oct―16 |
Vitamin D: A key player in COVID-19 immunity and lessons from the pandemic to combat immune-evasive variants |
Hussein Sabit, Shaimaa Abdel-Ghany, Mahmoud S. Abdallah, Osama Abul-Maaty, Ahmed I. Khoder, Nabil A. Shoman, Mohamed Sameh Farrag, Pavel Martasek, Ayman M. Noreddin, Mahmoud Nazih |
| 19 |
[GO] |
2024―Oct―03 |
Glucocorticoid treatment during COVID-19 infection: does it affect the incidence of long COVID? |
Polina Specktor, Dana Hadar, Hilla Cohen |
| 20 |
[GO] |
2024―Sep―23 |
The role of traditional NSAIDs and selective COX-2 inhibitors on COVID-19 outcomes: a real-world data study |
Narmeen Mallah, Irene Visos-Varela, Bahi Takkouche, Rosendo Bugarín-González, María Piñeiro-Lamas, Teresa Herdeiro, Maruxa Zapata-Cachafeiro, Almudena Rodríguez-Fernández, Angel Salgado-Barreira, Adolfo Figueiras, Eduardo Carracedo-Martínez, Rosa M. García-Álvarez, Francisco J. González-Barcala, Teresa M Herdeiro, Martina Lema-Oreiro, Samuel Pintos-Rodríguez, Maria Piñeiro-Lamas, Manuel Portela-Romero, Angela Prieto-Campo, Almudena Rodriguez-Fernández, Marc Saez, Margarita Taracido-Trunk |
| 21 |
[GO] |
2024―Sep―03 |
The impact of vitamin D administration on mortality in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials |
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Zhiyun Wong, Kaeshaelya Thiruchelvam |
| 22 |
[GO] |
2024―Aug―10 |
Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management |
Samar A. Antar, Nada A. Ashour, Amir O. Hamouda, Ayman M. Noreddin, Ahmed A. Al-Karmalawy |
| 23 |
[GO] |
2024―Aug―09 |
Impact of corticosteroid doses on prognosis of severe and critical COVID-19 patients with Omicron variant infection: a propensity score matching study |
Shiyao Wang, Ziying Chen, Xinran Zhang, Xiaojing Wu, Yuqiong Wang, Qi Zhang, Linna Huang, Xiaoyang Cui, Ying Cai, Xu Huang, Jingen Xia, Sichao Gu, Min Li, Qingyuan Zhan |
| 24 |
[GO] |
2024―Jul―24 |
Taming the storm: potential anti-inflammatory compounds targeting SARS-CoV-2 MPro |
Débora Bublitz Anton, Jeferson Camargo de Lima, Bruno Rampanelli Dahmer, Ana Micaela Camini, Marcia Inês Goettert, Luis Fernando Saraiva Macedo Timmers |
| 25 |
[GO] |
2024―May―21 |
Unraveling the enigma of long COVID: novel aspects in pathogenesis, diagnosis, and treatment protocols |
Abdul Mannan Baig, Sandy Rosko, Beate Jaeger, Joachim Gerlach, Hans Rausch |
| 26 |
[GO] |
2024―May―19 |
Surveying haemoperfusion impact on COVID-19 from machine learning using Shapley values |
Behzad Einollahi, Mohammad Javanbakht, Mehrdad Ebrahimi, Mohammad Ahmadi, Morteza Izadi, Sholeh Ghasemi, Zahra Einollahi, Bentolhoda Beyram, Abolfazl Mirani, Ehsan Kianfar |
| 27 |
[GO] |
2024―May―02 |
Outpatient glucocorticoid use and COVID-19 outcomes: a population-based study |
Almudena Rodríguez-Fernández, Irene Visos-Varela, Maruxa Zapata-Cachafeiro, Samuel Pintos-Rodríguez, Rosa M. García-Álvarez, Teresa M. Herdeiro, María Piñeiro-Lamas, Adolfo Figueiras, Ángel Salgado-Barreira, Rosendo Bugarín-González, Eduardo Carracedo-Martínez, Rosa M García-Álvarez, Francisco J González-Barcala, Teresa M Herdeiro, Martina Lema-Oreiro, Narmeen Mallah, Maria Piñeiro-Lamas, Manuel Portela-Romero, Angela Prieto-Campo, Almudena Rodriguez-Fernández, Marc Saez, Angel Salgado-Barreira, Margarita Taracido-Trunk |
| 28 |
[GO] |
2024―Apr―15 |
Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient |
Rosa María García-Álvarez, Maruxa Zapata-Cachafeiro, Irene Visos-Varela, Almudena Rodríguez-Fernández, Samuel Pintos-Rodríguez, Maria Piñeiro-Lamas, Teresa M. Herdeiro, Adolfo Figueiras, Angel Salgado-Barreira, Rosendo Bugarín-González, Eduardo Carracedo-Martínez, Francisco J. González-Barcala, Martina Lema-Oreiro, Narmeen Mallah, Manuel Portela-Romero, Angela Prieto-Campo, Marc Saez, Margarita Taracido-Trunk |
| 29 |
[GO] |
2024―Mar―16 |
Evaluation of the relationship of treatment and vaccination with prognosis in patients with a diagnosis of COVID-19 |
Seyma Oncu, Derya Korkmaz |
| 30 |
[GO] |
2024―Jan―31 |
Repurposing metformin to manage idiopathic or long COVID Tinnitus: self-report adopting a pathophysiological and pharmacological approach |
Mina T. Kelleni |
| 31 |
[GO] |
2023―Dec―20 |
Mesenchymal stem cell therapy for COVID-19 infection |
Seyyed Mohammad Matin Alavi-Dana, Yazdan Gholami, Mohammadreza Meghdadi, Mohammad Saleh Fadaei, Vahid Reza Askari |
| 32 |
[GO] |
2023―Dec―14 |
Intravenous immunoglobulin for treatment of hospitalized COVID-19 patients: an evidence mapping and meta-analysis |
Mei-xuan Li, Yan-fei Li, Xin Xing, Jun-qiang Niu, Liang Yao, Meng-ying Lu, Ke Guo, Mi-na Ma, Xiao-tian Wu, Ning Ma, Dan Li, Zi-jun Li, Ling Guan, Xiao-man Wang, Bei Pan, Wen-ru Shang, Jing Ji, Zhong-yang Song, Zhi-ming Zhang, Yong-feng Wang, Ke-hu Yang |
| 33 |
[GO] |
2023―Nov―27 |
Therapeutic potential and possible mechanisms of ginseng for depression associated with COVID-19 |
Fangyi Zhao, Kai Zhang, Hongyu Chen, Tianqi Zhang, Jiayu Zhao, Qianyu Lv, Qin Yu, Mengyu Ruan, Ranji Cui, Bingjin Li |
| 34 |
[GO] |
2023―Nov―13 |
Pharmacological evaluation of vitamin D in COVID-19 and long COVID-19: recent studies confirm clinical validation and highlight metformin to improve VDR sensitivity and efficacy |
Adel A. Gomaa, Yasmin A. Abdel-Wadood, Romany H. Thabet, Ghada A. Gomaa |
| 35 |
[GO] |
2023―Oct―17 |
Efficacy and safety of licorice (Glycyrrhiza glabra) in moderately ill patients with COVID-19: a randomized controlled trial |
Ali Ameri, Mehdi Farashahinejad, Parivash Davoodian, Omid Safa, Amin Kusha, Habib Dadvand, Soheil Hassanipour, Mohammad Fathalipour |
| 36 |
[GO] |
2023―Oct―17 |
The effect of probiotics on the risk of mortality in patients with COVID-19: systematic review and meta-analysis of randomized trials |
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan |
| 37 |
[GO] |
2023―Oct―16 |
The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression |
Arto Yuwono Soeroto, Hendarsyah Suryadinata, Theo Audi Yanto, Timotius Ivan Hariyanto |
| 38 |
[GO] |
2023―Oct―13 |
Cytokine profiles in COVID-19 patients undergoing adjunct ozone therapy: some comments |
Salvatore Chirumbolo, Sergio Pandolfi, Marianno Franzini, Luigi Valdenassi |
| 39 |
[GO] |
2023―Oct―09 |
Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies |
Zahra Shafaghat, Amir-Hossein Khosrozadeh Ghomi, Hossein Khorramdelazad, Elaheh Safari |
| 40 |
[GO] |
2023―Oct―07 |
Systematic review and meta-analysis of anti-CD20 treatments in patients with COVID-19: an assessment of severe illness and mortality outcomes |
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Kaeshaelya Thiruchelvam |
| 41 |
[GO] |
2023―Sep―29 |
Gene expression of protein kinase AMP-activated catalytic subunit alpha 1 (PRKAA1), solute carrier family 2 member 1 (SLC2A1) and mechanistic target of rapamycin (MTOR) in metformin-treated type 2 diabetes patients with COVID-19: impact on inflammation markers |
Pavlo Petakh, Iryna Kamyshna, Aleksandr Kamyshnyi |
| 42 |
[GO] |
2023―Aug―21 |
Ibuprofen, other NSAIDs and COVID-19: a narrative review |
William Laughey, Imran Lodhi, Graham Pennick, Lucinda Smart, Olutoba Sanni, Suneet Sandhu, Bruce Charlesworth |
| 43 |
[GO] |
2023―Aug―07 |
Combined systemic inflammatory indexes as reflectors of outcome in patients with COVID-19 infection admitted to ICU |
Amir Tahavvori, Reza Mosaddeghi-Heris, Faezeh Ghanbari Sevari, Seyed Mohammad Amin Alavi, Peghah Panahi, Niloufar Abbasi, Hamed Rahmani Youshanlouei, Seyyed Sina Hejazian |
| 44 |
[GO] |
2023―Jul―17 |
Multisystem inflammatory syndrome in children (MIS-C): Implications for long COVID |
Tamás Constantin, Tamás Pék, Zsuzsanna Horváth, Diána Garan, Attila J. Szabó |
| 45 |
[GO] |
2023―Jul―15 |
Effect of treatment regimen of the rheumatoid arthritis patients on the risk of coronavirus disease 2019 by modulating the inflammatory mediators |
Zahra Bagheri-Hosseinabadi, Alireza Dehghani, Mohammad Amin Lotfi, Mitra Abbasifard |
| 46 |
[GO] |
2023―Jul―12 |
Cytokine profile and antioxidants status in the moderate and severe COVID-19 patients: a trial of ozone therapy impact as a medicinal supplement |
Hadi Esmaeili Gouvarchin Ghaleh, Morteza Izadi, Mohammad Javanbakht, Mostafa Ghanei, Behzad Einollahi, Nematollah Jonaidi Jafari, Gholamhossein Alishiri, Jafar Aslani, Hassan Abolghasemi, Vincenzo Simonetti, Mostafa Khafaei, Shi Zhao, Seyed Hassan Saadat, Majid Ahmadi, Shahram Parvin, Soheil Vazifedoust, Akbar Ghorbani Alvanagh |
| 47 |
[GO] |
2023―Jun―21 |
Long COVID and possible preventive options |
Szilvia Sebők, Klara Gyires |
| 48 |
[GO] |
2023―Jun―16 |
The African Kelleni’s roadmap using nitazoxanide and broad-spectrum antimicrobials to abort returning to COVID-19 square one |
Mina T. Kelleni |
| 49 |
[GO] |
2023―Jun―02 |
Intermediate- to high-dose dexamethasone versus low-dose dexamethasone in patients with COVID-19 requiring respiratory support: a systematic review and meta-analysis of randomized trials |
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan |
| 50 |
[GO] |
2023―Jun―01 |
Nutritional deficiencies and long COVID: correspondence |
Amnuay Kleebayoon, Viroj Wiwanitkit |
| 51 |
[GO] |
2023―May―19 |
Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach |
Gaber El-Saber Batiha, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Nada A. Ashour, Walaa A. Negm |
| 52 |
[GO] |
2023―May―15 |
The post-COVID stress syndrome: from the three-stage stress response of Hans Selye to COVID-19 |
Sandor Szabo |
| 53 |
[GO] |
2023―Apr―20 |
Diabetes as one of the long-term COVID-19 complications: from the potential reason of more diabetic patients’ susceptibility to COVID-19 to the possible caution of future global diabetes tsunami |
Yasamin Sharbatdar, Ronak Mousavian, Seyed Mostafa Noorbakhsh Varnosfaderani, Fatemeh Aziziyan, Mahsa Liaghat, Payam Baziyar, Ali Yousefi Rad, Chanour Tavakol, Amir Mansour Moeini, Mohsen Nabi-Afjadi, Hamidreza Zalpoor, Fatemeh Kazemi-Lomedasht |
| 54 |
[GO] |
2023―Apr―18 |
The effect of vitamin C on the risk of mortality in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials |
Chia Siang Kow, Syed Shahzad Hasan, Dinesh Sangarran Ramachandram |
| 55 |
[GO] |
2023―Apr―10 |
Anakinra for the prophylaxis of venous thromboembolism in patients with COVID-19 |
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan |
| 56 |
[GO] |
2023―Apr―05 |
Fatigue, sleepiness and sleep quality are SARS-CoV-2 variant independent in patients with long COVID symptoms |
Anna Reka Percze, Alexandra Nagy, Lorinc Polivka, Eniko Barczi, Ibolya Czaller, Zsuzsanna Kovats, Janos Tamas Varga, Judit H. Ballai, Veronika Muller, Gabor Horvath |
| 57 |
[GO] |
2023―Mar―26 |
Real-world practice of the Egyptian Kelleni’s protocol amid changing tropism of SARS-CoV-2 omicron BA.5.2.1.7, XBB 1.5 and CH.1.1 subvariants: a multi-purpose protocol |
Mina T. Kelleni |
| 58 |
[GO] |
2023―Mar―25 |
What is the role of brown adipose tissue in metabolic health: lessons learned and future perspectives in the long COVID? |
Iryna Muzyka, Oleh Revenko, Iryna Kovalchuk, Maryanna Savytska, Anna Bekesevych, Roksolana Kasko, Oksana Zayachkivska |
| 59 |
[GO] |
2023―Mar―24 |
Post-COVID interstitial lung disease in symptomatic patients after COVID-19 disease |
Dorottya Fesu, Lorinc Polivka, Eniko Barczi, Marcell Foldesi, Gabor Horvath, Edit Hidvegi, Aniko Bohacs, Veronika Muller |
| 60 |
[GO] |
2023―Mar―22 |
Long COVID prevalence and physiology-centered risks: population-based study in Ukraine |
Iryna Muzyka, Mariana Yakhnytska, Maryana Savytska, Oksana Zayachkivska |
| 61 |
[GO] |
2023―Mar―21 |
What is the role of brown adipose tissue in metabolic health: lessons learned and future perspectives in the long COVID? |
Iryna Muzyka, Oleh Revenko, Iryna Kovalchuk, Maryanna Savytska, Anna Bekesevych, Oksana Zayachkivska |
| 62 |
[GO] |
2023―Mar―15 |
Nutritional deficiencies that may predispose to long COVID |
John V. Schloss |
| 63 |
[GO] |
2023―Mar―09 |
COVID-19-induced neurological symptoms: focus on the role of metal ions |
Yi-Yue Zhang, Kai-Di Ren, Xiu-Ju Luo, Jun Peng |
| 64 |
[GO] |
2023―Feb―27 |
Could the fibromyalgia syndrome be triggered or enhanced by COVID-19? |
Maria Fernanda Pessano Fialho, Evelyne Silva Brum, Sara Marchesan Oliveira |
| 65 |
[GO] |
2023―Feb―01 |
The direct correlation between microbiota and SARS-CoV-2 infectious disease |
Antonio Vitiello, Francesco Ferrara, Andrea Zovi |
| 66 |
[GO] |
2023―Jan―27 |
High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center |
Murat Bektaş, Servet Yüce, Mustafa Ay, Muhammed Hamdi Uyar, Mustafa Erkut Önder, Muhammed İkbal Kılıç |
| 67 |
[GO] |
2023―Jan―07 |
A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective? |
Mohsen Nabi-Afjadi, Fatemeh Mohebi, Hamidreza Zalpoor, Fatemeh Aziziyan, Abdullatif Akbari, Hemen Moradi-Sardareh, Elham Bahreini, Amir Mansour Moeini, Hossein Effatpanah |
| 68 |
[GO] |
2023―Jan―04 |
Critical roles of cytokine storm and bacterial infection in patients with COVID-19: therapeutic potential of mesenchymal stem cells |
Babak Arjmand, Sepideh Alavi-Moghadam, Masoumeh Sarvari, Mostafa Rezaei-Tavirani, Ahmad Rezazadeh- Mafi, Rasta Arjmand, Mohsen Nikandish, Ensieh Nasli-Esfahani, Bagher Larijani |
| 69 |
[GO] |
2022―Dec―20 |
The effect of ramatroban on cytokine and thrombotic storms in Covid-19 |
Hayder M. Al-Kuraishy, Ali I. Al-Gareeb, Hebatallah M. Saad, Gaber El-Saber Batiha |
| 70 |
[GO] |
2022―Dec―09 |
A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection |
Gaber El-Saber Batiha, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Fadia S. Youssef, Suzy A. El-Sherbeni, Walaa A. Negm |
| 71 |
[GO] |
2022―Nov―29 |
Efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in COVID-19 patients: a meta-analysis |
An-ran Xi, Yi-jun Luo, Jin-Tao Guan, Wei-Jie Wang, Zheng-Hao Xu |
| 72 |
[GO] |
2022―Nov―24 |
Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal |
Gaber El-Saber Batiha, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Mubarak Alruwaili, Raed AlRuwaili, Sarah M. Albogami, Mohammed Alorabi, Hebatallah M. Saad, Jesus Simal-Gandara |
| 73 |
[GO] |
2022―Nov―19 |
Efficacy and safety of oral melatonin in patients with severe COVID-19: a randomized controlled trial |
Ali Ameri, Masoomeh Frouz Asadi, Ava Ziaei, Majid Vatankhah, Omid Safa, Manoochehr Kamali, Mohammad Fathalipour, Masoumeh Mahmoodi, Soheil Hassanipour |
| 74 |
[GO] |
2022―Oct―25 |
Immunogenicity and safety of the CoronaVac and BNT162b2 Covid-19 vaccine in patients with inflammatory rheumatic diseases and healthy adults: comparison of different vaccines |
Sevilay Batıbay, Rezan Koçak Ulucaköy, Zafer Günendi, Işıl Fidan, Gülendam Bozdayı, Feride Nur Göğüş |
| 75 |
[GO] |
2022―Oct―02 |
The role of berberine in Covid-19: potential adjunct therapy |
Ahmad O. Babalghith, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Michel De Waard, Sadiq Mohammed Al-Hamash, Sabatier Jean-Marc, Walaa A. Negm, Gaber El-Saber Batiha |
| 76 |
[GO] |
2022―Sep―30 |
Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy? |
Basil Mohammed Alomair, Hayder M. Al-kuraishy, Ali K. Al-Buhadily, Ali I. Al-Gareeb, Michel De Waard, Engy Elekhnawy, Gaber El-Saber Batiha |
| 77 |
[GO] |
2022―Sep―22 |
Glycyrrhizin and boswellic acids, the golden nutraceuticals: multitargeting for treatment of mild-moderate COVID-19 and prevention of post-COVID cognitive impairment |
Adel A. Gomaa, Yasmin A. Abdel-Wadood, Mohamed A. Gomaa |
| 78 |
[GO] |
2022―Sep―16 |
Potential role of lipoxin in the management of COVID-19: a narrative review |
Gaber El-Saber Batiha, Ali I. Al-Gareeb, Engy Elekhnawy, Hayder M. Al-kuraishy |
| 79 |
[GO] |
2022―Sep―12 |
Association between chemosensory dysfunctions and inflammatory biomarkers in patients with SARS-CoV-2 infection: a systematic review and meta-analysis |
Elisama Gomes Magalhães de Melo, Rayle Monteiro Andrade, Sara Juliana de Abreu de Vasconcellos, Priscila Lima dos Santos, Diego Moura Tanajura, Lucindo José Quintans-Júnior, Jullyana de Souza Siqueira Quintans, Paulo Ricardo Martins-Filho |
| 80 |
[GO] |
2022―Sep―01 |
Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19) |
Banlambhabok Khongthaw, Kanika Dulta, Pankaj Kumar Chauhan, Vinod Kumar, Joshua O. Ighalo |
| 81 |
[GO] |
2022―Aug―26 |
Dysregulation of immunity in COVID-19 and SLE |
Seyyed Sina Hejazian, Seyyedeh Mina Hejazian, Farahnoosh Farnood, Sima Abedi Azar |
| 82 |
[GO] |
2022―Aug―26 |
Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols |
Engy Elekhnawy, Walaa A. Negm, Suzy A. El-Sherbeni, Ahmed Zayed |
| 83 |
[GO] |
2022―Aug―22 |
Hesperetin as an anti-SARS-CoV-2 agent can inhibit COVID-19-associated cancer progression by suppressing intracellular signaling pathways |
Hamidreza Zalpoor, Maryam Bakhtiyari, Hooriyeh Shapourian, Puria Rostampour, Chanour Tavakol, Mohsen Nabi-Afjadi |
| 84 |
[GO] |
2022―Aug―18 |
Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view |
Francesco Ferrara, Andrea Zovi, Ugo Trama, Antonio Vitiello |
| 85 |
[GO] |
2022―Aug―10 |
Pathogenic role of cytokines in COVID-19, its association with contributing co-morbidities and possible therapeutic regimens |
Ayesha Tanveer, Bushra Akhtar, Ali Sharif, Uzma Saleem, Azhar Rasul, Aftab Ahmad, Kashif Jilani |
| 86 |
[GO] |
2022―Aug―03 |
Ursolic acid and SARS-CoV-2 infection: a new horizon and perspective |
Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Walaa A. Negm, Athanasios Alexiou, Gaber El-Saber Batiha |
| 87 |
[GO] |
2022―Jul―27 |
Effects of Boswellia species on viral infections with particular attention to SARS-CoV-2 |
Zahra Jamshidi, Maryam Hashemi, Rezvan Yazdian-Robati, Leila Etemad, Zahra Salmasi, Prashant Kesharwani |
| 88 |
[GO] |
2022―Jul―14 |
Short-term celecoxib (celebrex) adjuvant therapy: a clinical trial study on COVID-19 patients |
Habib Ghaznavi, Zahra Mohammadghasemipour, Milad Shirvaliloo, Mohammad Kazem Momeni, Malihe Metanat, Farzaneh Gorgani, Fatemeh Abedipour, Mahdi Mohammadi, Majid Sartipi, Ali Reza Salimi Khorashad, Omolbanin Shahraki, Mohadese Ataee, Roghayeh Sheervalilou, Saman Sargazi |
| 89 |
[GO] |
2022―Jun―20 |
Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trial |
Mohammadreza Moslemi, Seyyedeh Mina Hejazian, Molod Shaddelan, Fatemeh Javanali, Alireza Mirghaffari, Armin Sadeghi, Hamed Valizadeh, Akbar Sharifi, Morteza Haramshahi, Mohammadreza Ardalan, Sepideh Zununi Vahed |
| 90 |
[GO] |
2022―Jun―14 |
The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review |
Mohammed Ahmed Akkaif, Abubakar Sha’aban, Arturo Cesaro, Ammar Ali Saleh Jaber, Andrea Vergara, Ismaeel Yunusa, Abubakar Ibrahim Jatau, Mustapha Mohammed, G. Saravana Govindasamy, Majed Ahmed Al-Mansoub, Muhamad Ali Sheikh Abdul Kader, Baharudin Ibrahim |
| 91 |
[GO] |
2022―May―30 |
The key role of Calpain in COVID-19 as a therapeutic strategy |
Aref Doozandeh Juibari, Mohammad Hossein Rezadoost, Masoud Soleimani |
| 92 |
[GO] |
2022―May―30 |
Histopathological and molecular links of COVID-19 with novel clinical manifestations for the management of coronavirus-like complications |
Ankita Sood, Onkar Bedi |
| 93 |
[GO] |
2022―May―13 |
COVID-19 and corticosteroids: a narrative review |
Gaber El-Saber Batiha, Ali I. Al-Gareeb, Hebatallah M. Saad, Hayder M. Al-kuraishy |
| 94 |
[GO] |
2022―May―04 |
COVID-19 and the role of cytokines in this disease |
Amin Hasanvand |
| 95 |
[GO] |
2022―Apr―29 |
A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19 |
Gomaa Mostafa-Hedeab, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Philippe Jeandet, Hebatallah M. Saad, Gaber El-Saber Batiha |
| 96 |
[GO] |
2022―Apr―26 |
High-mobility group box 1 (HMGB1) in COVID-19: extrapolation of dangerous liaisons |
Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Luay Alkazmi, Ola A. Habotta, Gaber El-Saber Batiha |
| 97 |
[GO] |
2022―Apr―07 |
Potential plants for inflammatory dysfunction in the SARS-CoV-2 infection |
Diorge Jônatas Marmitt |
| 98 |
[GO] |
2022―Mar―28 |
Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies |
Yrna Lorena Matos de Oliveira, Ayane de Sá Resende, Paulo Ricardo Martins-Filho, Tatiana Rodrigues de Moura |
| 99 |
[GO] |
2022―Mar―23 |
Anti-inflammatory response of cardamom extract and prediction of therapeutic window in COVID-19 patients by assessing inflammatory markers using RT-PCR |
Nourin Shakeeb, Prashanth Varkey, Aimy Hynse, Ajit Mandlecha |
| 100 |
[GO] |
2022―Mar―22 |
Comment on “Inflawell, neutrophil-to-lymphocyte ratio and COVID-19” |
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit |
| 101 |
[GO] |
2022―Mar―01 |
Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial |
Adel A. Gomaa, Hamdy S. Mohamed, Rasha B. Abd-ellatief, Mohamed A. Gomaa, Doaa S. Hammam |
| 102 |
[GO] |
2022―Feb―24 |
Inflawell® improves neutrophil-to-lymphocyte ratio and shortens hospitalization in patients with moderate COVID-19, in a randomized double-blind placebo-controlled clinical trial |
Sepideh Barzin Tond, Laurent Balenci, Nasim Khajavirad, Mohammadreza Salehi, Abbas Tafakhori, Mohammad Reza Shahmohammadi, Fereshteh Ghiasvand, Sirous Jafari, Sara Abolghasemi, Farzad Mokhtari, Somayyeh Mahmoodi Baram, Tayebe Zarei, Davood Kazemi, Esmaeil Mohammadnejad, Akram Shah-Hosseini, Alireza Haghbin Toutounchi, So�h Fallah, Ali Riazi, Saeed Karima |
| 103 |
[GO] |
2022―Feb―14 |
Selenium, selenoprotein P, and oxidative stress levels in SARS-CoV-2 patients during illness and recovery |
A. Skesters, D. Kustovs, A. Lece, E. Moreino, E. Petrosina, K. D. Rainsford |
| 104 |
[GO] |
2022―Jan―31 |
Evaluation serum levels of Insulin Growth Factor-1 (IGF-1) and its association with clinical parameters in severe COVID-19 |
Parisa Feizollahi, Somaieh matin, Seyed Askar Roghani, Shayan Mostafaei, Elham Safarzadeh, Mahdi Taghadosi |
| 105 |
[GO] |
2022―Jan―31 |
The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis |
Chia Siang Chia Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan |
| 106 |
[GO] |
2022―Jan―20 |
Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection |
Arbind Kumar, Aashish Sharma, Narendra Vijay Tirpude, Suresh Sharma, Yogendra S. Padwad, Sanjay Kumar |
| 107 |
[GO] |
2022―Jan―03 |
Covid-19: pharmacotherapeutic insights on various curative approaches in terms of vulnerability, comorbidities, and vaccination |
Rupinder Kaur, Shareen Singh, Thakur Gurjeet Singh, Pragati Sood, Jiki Robert |
| 108 |
[GO] |
2021―Dec―20 |
Correction to: The effect of glutamine supplementation on serum levels of some inflammatory factors, oxidative stress, and appetite in COVID-19 patients: a case-control study |
Mahsa Mohajeri, Ehsan Horriatkhah, Reza Mohajery |
| 109 |
[GO] |
2021―Nov―25 |
NSAIDs and Kelleni’s protocol as potential early COVID-19 treatment game changer: could it be the final countdown? |
Mina T. Kelleni |
| 110 |
[GO] |
2021―Oct―28 |
The effect of glutamine supplementation on serum levels of some inflammatory factors, oxidative stress, and appetite in COVID-19 patients: a case-control study |
Mahsa Mohajeri, Ehsan Horriatkhah, Reza Mohajery |
| 111 |
[GO] |
2021―Aug―09 |
Management of COVID-19-induced cytokine storm by Keap1-Nrf2 system: a review |
Ekta Singh, Gurubasavaraja Swamy Purawarga Matada, Nahid Abbas, Prasad Sanjay Dhiwar, Abhishek Ghara, Arka Das |
| 112 |
[GO] |
2021―Jul―31 |
Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19 |
Ammara Saleem, Muhammad Furqan Akhtar, Muhammad Haris, Mohamed M. Abdel-Daim |
| 113 |
[GO] |
2021―Jul―19 |
COVID-19 vaccines and decreased transmission of SARS-CoV-2 |
A. Vitiello, F. Ferrara, V. Troiano, R. La Porta |
| 114 |
[GO] |
2021―Jul―09 |
SARS-CoV-2 may trigger inflammasome and pyroptosis in the central nervous system: a mechanistic view of neurotropism |
Ali Sepehrinezhad, Ali Gorji, Sajad Sahab Negah |
| 115 |
[GO] |
2021―Jul―05 |
Boswellic acids/Boswellia serrata extract as a potential COVID-19 therapeutic agent in the elderly |
Adel A. Gomaa, Hamdy S. Mohamed, Rasha Bakheet Abd-ellatief, Mohamed A. Gomaa |
| 116 |
[GO] |
2021―Jun―29 |
Shedding light on vitamin D: the shared mechanistic and pathophysiological role between hypovitaminosis D and COVID-19 risk factors and complications |
Esraa Menshawey, Rahma Menshawey, Omnia Azmy Nabeh |
| 117 |
[GO] |
2021―Jun―10 |
Role of vitamins and minerals as immunity boosters in COVID-19 |
Puneet Kumar, Mandeep Kumar, Onkar Bedi, Manisha Gupta, Sachin Kumar, Gagandeep Jaiswal, Vikrant Rahi, Narhari Gangaram Yedke, Anjali Bijalwan, Shubham Sharma, Sumit Jamwal |
| 118 |
[GO] |
2021―May―03 |
Brief review of the mRNA vaccines COVID-19 |
Antonio Vitiello, Francesco Ferrara |
| 119 |
[GO] |
2021―Apr―21 |
The risk of mortality in patients with COVID-19 with pre-diagnosis use of NSAIDs: a meta-analysis |
Chia Siang Kow, Syed Shahzad Hasan |
| 120 |
[GO] |
2021―Apr―06 |
Neuropathophysiology of coronavirus disease 2019: neuroinflammation and blood brain barrier disruption are critical pathophysiological processes that contribute to the clinical symptoms of SARS-CoV-2 infection |
Menizibeya O. Welcome, Nikos E. Mastorakis |
| 121 |
[GO] |
2021―Mar―15 |
Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting |
Sreedhar Amere Subbarao |
| 122 |
[GO] |
2021―Feb―20 |
Correction to: COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties |
Muhammad Asif, Mohammad Saleem, Malik Saadullah, Hafiza Sidra Yaseen, Raghdaa Al Zarzour |
| 123 |
[GO] |
2020―Nov―16 |
COVID-19 and nutriceutical therapies, especially using zinc to supplement antimicrobials |
Desley Butters, Michael Whitehouse |
| 124 |
[GO] |
2020―Nov―07 |
The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients |
Apurva Hariharan, Abdul Rahman Hakeem, Subathra Radhakrishnan, Mettu Srinivas Reddy, Mohamed Rela |
| 125 |
[GO] |
2020―Sep―12 |
ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror |
Mina T. Kelleni |
| 126 |
[GO] |
2020―Aug―14 |
A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality |
Lucinda Smart, Neil Fawkes, Paul Goggin, Graham Pennick, K. D. Rainsford, Bruce Charlesworth, Neil Shah |
| 127 |
[GO] |
2020―Aug―14 |
COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties |
Muhammad Asif, Mohammad Saleem, Malik Saadullah, Hafiza Sidra Yaseen, Raghdaa Al Zarzour |
| 128 |
[GO] |
2020―Jul―07 |
A viral infection explanation for Kawasaki disease in general and for COVID-19 virus-related Kawasaki disease symptoms |
Kevin Roe |
